Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > Would someone pay $ 2B for DIMI?

<< Previous

Bullboard Posts

Next >>

Comment by mercedesmanon Feb 09, 2022 12:02pm

163 Views

Post# 34412838

RE:RE:RE:Would someone pay $ 2B for DIMI?

PezDalatoYou wrote: There is one big difference. The $2 bil that Fresenius paid for NxStage was for the entire company, at least that's how I read their NR. I'm assuming this would include IP, manufacturing facilities, sales force, etc. Why wouldn't DaVi just buy out Infomed itself? The Infomed NA rights can't be worth $2 bil using NxStage as a comparator. And what protection would Spectral have in the event of an Infomed buyout scenario? Would we be left holding our empty marble bags?

Spectral wouuld have signed a Distribution Agreement that protects its NA Rights in the event of a change in control by Infomed. Assignment clause.

Not sure DaVita wants worldwide Rights or would just prefer focus on the most lucrative US market

Doesn't always make sense to acquire manufacturing capabilites. PMX buyer aren't likely to buy Toray's factories. Most distributors prefer to stick to their knitting.

While NA is not the whole world, factor in worldwide rights to Hemoperfusion using DIMI or SAMI (unless those are "royaltied" away). Plus what premium should be factored into a deal for "disrputive" technology that leads to much much higher market acceptance/penetration? (ie. reduces barriers to adoption)

Even doing the math using $ 1B or $ 1.5B - it's still a substantial asset

Why do SH players always insert FUD, and talk down our asset ? Especially in relation to share value ?

I have a theory....no one wants to jinx any ongoing & complex negotiations.

vs a faction that wants the SP to more fairly reflect the potential.